Skip to main content

Fritz Roth

    Education & Training

  • 1986 – 1990 Univ. of California, Berkeley, BA 1990, Physics and Molecular & Cell Biology
  • 1992 – 1998 Harvard University, PhD 1998, Biophysics
  • Dr. Chris Sander’s group at Millennium Pharmaceuticals (now Takeda)
Research Interests

My research team develops and applies both experimental and computational technology, launching spectacular multidisciplinary scientists.  The lab’s primary research focus is on generating comprehensive experimental maps of functional sequence variation (‘variant effect maps’) and establishing their clinical utility. To date, we have generated variant effect maps for over 20 human proteins, using highly-multiplexed cell-based assays (often under multiple environments, genetic contexts or using distinct functional assays). For each of these projects, there is a major computational modeling component, e.g. molecular dynamics. We also developed VARITY, among the current top predictors of pathogenicity for rare human missense variants. Another focus with both experimental and computational aspects is the systematic discovery of protein interactions, applying massively-multiplexed interaction assays enabled by next-generation sequencing under different interaction conditions to understand the regulated dynamics of protein interaction.